Skip to main content

Advertisement

SpringerLink
Log in

Bone Cells and Bone Turnover in Diabetes Mellitus

  • Bone and Diabetes (AV Schwartz and P Vestergaard, Section Editors)
  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Substantial evidence exists that in addition to the well-known complications of diabetes, increased fracture risk is an important morbidity. This risk is probably due, at least in part, to altered bone remodeling and bone cell function in diabetes. Circulating biochemical markers of bone formation, including P1NP, osteocalcin and bone-specific alkaline phosphatase have been found to be decreased in type 2 diabetes (T2D) and may be predictive of fractures independently of bone mineral density (BMD). These findings have been corroborated by preliminary histomorphometric data. Reductions in the bone resorption marker serum CTx in T2D have also been reported. Serum sclerostin levels have been found to be increased in T2D and appear to be predictive of fracture risk independent of BMD. Other factors such as bone marrow fat saturation, advanced glycation endproduct (AGE) accumulation, and microarchitectural changes might also relate to bone cell function and fracture risk in diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. IDF Diabetes Atlas Update 2012. http://www.idf.org/diabetesatlas/5e/Update2012 (accessed January 10, 2013).

  2. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495–505.

    Article  PubMed  Google Scholar 

  3. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007;18(4):427–44.

    Article  CAS  PubMed  Google Scholar 

  4. Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA : J Am Med Assoc. 2011;305(21):2184–92.

    Article  CAS  Google Scholar 

  5. Giangregorio LM, Leslie WD, Lix LM, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res. 2012;27(2):301–8.

    Article  PubMed  Google Scholar 

  6. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin EndocrinolMetabol. 2006;91(9):3404–10.

    Article  CAS  Google Scholar 

  7. Leslie WD, Lix LM, Prior HJ, Derksen S, Metge C, O'Neil J. Biphasic fracture risk in diabetes: a population-based study. Bone. 2007;40(6):1595–601.

    Article  PubMed  Google Scholar 

  8. de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 2005;16(12):1713–20.

    Article  PubMed  Google Scholar 

  9. Hernandez RK, Do TP, Critchlow CW, Dent RE, Jick SS. Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research database. Acta Orthop. 2012;83(6):653–60.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Semel J, Gray JM, Ahn HJ, Nasr H, Chen JJ. Predictors of outcome following hip fracture rehabilitation. PM & R : J Injury, Function, Rehabilitation. 2010;2(9):799–805.

    Article  Google Scholar 

  11. Bass E, French DD, Bradham DD. A national perspective of Medicare expenditures for elderly veterans with hip fractures. J Am Med Directors Assoc. 2008;9(2):114–9.

    Article  Google Scholar 

  12. Pan H, Wu N, Yang T, He W. Association between bone mineral density and type 1 diabetes mellitus: a meta-analysis of cross-sectional studies. Diabetes Metab Res Rev. 2014;30(7):531–42.

    Article  PubMed  Google Scholar 

  13. Neumann T, Samann A, Lodes S, et al. Glycaemic control is positively associated with prevalent fractures but not with bone mineral density in patients with type 1 diabetes. Diabetic, Medicine: J British Diabetic Assoc. 2011;28(7):872–5.

    Article  CAS  Google Scholar 

  14. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metabolism. 2001;86(1):32–8.

    Article  CAS  Google Scholar 

  15. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180(1):32–9.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Clowes JA, Allen HC, Prentis DM, Eastell R, Blumsohn A. Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. J Clin Endocrinol Metabolism. 2003;88(10):4867–73.

    Article  CAS  Google Scholar 

  17. Inaba M, Nishizawa Y, Mita K, et al. Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes. Osteoporos Int. 1999;9(6):525–31.

    Article  CAS  PubMed  Google Scholar 

  18. Inaba M, Terada M, Koyama H, et al. Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells. J Bone Miner Res. 1995;10(7):1050–6.

    Article  CAS  PubMed  Google Scholar 

  19. Terada M, Inaba M, Yano Y, et al. Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone. 1998;22(1):17–23.

    Article  CAS  PubMed  Google Scholar 

  20. Schwarz P, Sorensen HA, Momsen G, Friis T, Transbol I, McNair P. Hypocalcemia and parathyroid hormone responsiveness in diabetes mellitus: a tri-sodium-citrate clamp study. Acta Endocrinol (Copenh). 1992;126(3):260–3.

    CAS  Google Scholar 

  21. Botolin S, Faugere MC, Malluche H, Orth M, Meyer R, McCabe LR. Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice. Endocrinology. 2005;146(8):3622–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. McCabe L, Zhang J, Raehtz S. Understanding the skeletal pathology of type 1 and 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr. 2011;21(2):187–206.

    Article  CAS  PubMed  Google Scholar 

  23. Gunczler P, Lanes R, Paoli M, Martinis R, Villaroel O, Weisinger JR. Decreased bone mineral density and bone formation markers shortly after diagnosis of clinical type 1 diabetes mellitus. J Pediatric End Ocrinol Metabolism : JPEM. 2001;14(5):525–8.

    CAS  Google Scholar 

  24. Gunczler P, Lanes R, Paz-Martinez V, et al. Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally. J Pediatric Endocrinol Metabolism : JPEM. 1998;11(3):413–9.

    Article  CAS  Google Scholar 

  25. Masse PG, Pacifique MB, Tranchant CC, et al. Bone metabolic abnormalities associated with well-controlled type 1 diabetes (IDDM) in young adult women: a disease complication often ignored or neglected. J Am Coll Nutr. 2010;29(4):419–29.

    Article  CAS  PubMed  Google Scholar 

  26. Armas LA, Akhter MP, Drincic A, Recker RR. Trabecular bone histomorphometry in humans with type 1 diabetes mellitus. Bone. 2012;50(1):91–6.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Dobnig H, Piswanger-Solkner JC, Roth M, et al. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab. 2006;91(9):3355–63.

    Article  CAS  PubMed  Google Scholar 

  28. Ardawi MS, Akhbar DH, Alshaikh A, et al. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone. 2013;56(2):355–62.

    Article  CAS  PubMed  Google Scholar 

  29. Yamamoto M, Yamaguchi T, Nawata K, Yamauchi M, Sugimoto T. Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(4):1277–84.

    Article  CAS  PubMed  Google Scholar 

  30. Gaudio A, Privitera F, Battaglia K, et al. Sclerostin levels associated with inhibition of the Wnt/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(10):3744–50.

    Article  CAS  PubMed  Google Scholar 

  31. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes. 1995;44(7):775–82.

    Article  CAS  PubMed  Google Scholar 

  32. Manavalan JS, Cremers S, Dempster DW, et al. Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metabolism. 2012;97(9):3240–50.

    Article  CAS  Google Scholar 

  33. Kanazawa I, Yamaguchi T, Sugimoto T. Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int. 2011;22(4):1191–8.

    Article  CAS  PubMed  Google Scholar 

  34. Eghbali-Fatourechi GZ, Modder UI, Charatcharoenwitthaya N, et al. Characterization of circulating osteoblast lineage cells in humans. Bone. 2007;40(5):1370–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Rubin MR, Manavalan JS, Dempster DW, et al. Parathyroid hormone stimulates circulating osteogenic cells in hypoparathyroidism. J Clin Endocrinol Metabolism. 2011;96(1):176–86.

    Article  CAS  Google Scholar 

  36. Ardawi M, Akbar D, Rouzi A, Senani N, Ahmad A, Qari M. Elevated sphingosine 1-phosphate levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Bone Miner Res, 2014. http://www.asbmr.org/education/AbstractDetail?aid=51ef5a65-8072-4369-b2b7-c1381053da59 (accessed December 11, 2014).

  37. Canalis E. Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol. 2013;9(10):575–83.

    Article  CAS  PubMed  Google Scholar 

  38. Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R, et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(1):234–41.

    Article  CAS  PubMed  Google Scholar 

  39. Gennari L, Merlotti D, Valenti R, et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2012;97(5):1737–44.

    Article  CAS  PubMed  Google Scholar 

  40. Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98(10):4030–7.

    Article  CAS  PubMed  Google Scholar 

  41. Patsch JM, Li X, Baum T, et al. Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures. J Bone Miner Res 2013.

  42. Ma YH, Schwartz AV, Sigurdsson S, et al. Circulating sclerostin associated with vertebral bone marrow fat in older men but not women. J Clin Endocrinol Metab. 2014;99(12):E2584–90.

    Article  CAS  PubMed  Google Scholar 

  43. Saito M, Mori S, Mashiba T, Komatsubara S, Marumo K. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int. 2008;19(9):1343–54.

    Article  CAS  PubMed  Google Scholar 

  44. Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int. 2009;20(6):887–94.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Vashishth D. The role of the collagen matrix in skeletal fragility. Curr Osteoporosis Reports. 2007;5(2):62–6.

    Article  Google Scholar 

  46. Garnero P, Borel O, Gineyts E, et al. Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone. 2006;38(3):300–9.

    Article  CAS  PubMed  Google Scholar 

  47. Schalkwijk CG, Stehouwer CD, van Hinsbergh VW. Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification. Diabetes Metab Res Rev. 2004;20(5):369–82.

    Article  CAS  PubMed  Google Scholar 

  48. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci U S A. 1984;81(2):583–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Schwartz AV. Diabetes mellitus: does it affect bone? Calcif Tissue Int. 2003;73(6):515–9.

    Article  CAS  PubMed  Google Scholar 

  50. Reiser KM. Nonenzymatic glycation of collagen in aging and diabetes. Proc Soc Exp Biol Med. 1998;218(1):23–37.

    Article  CAS  PubMed  Google Scholar 

  51. Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P. Pentosidine effects on human osteoblasts in vitro. Ann N Y Acad Sci. 2008;1126:166–72.

    Article  CAS  PubMed  Google Scholar 

  52. McCarthy AD, Uemura T, Etcheverry SB, Cortizo AM. Advanced glycation endproducts interefere with integrin-mediated osteoblastic attachment to a type-I collagen matrix. Int J Biochem Cell Biol. 2004;36(5):840–8.

    Article  CAS  PubMed  Google Scholar 

  53. McCarthy AD, Etcheverry SB, Cortizo AM. Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development. Acta Diabetol. 2001;38(3):113–22.

    Article  CAS  PubMed  Google Scholar 

  54. Kume S, Kato S, Yamagishi S, et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res. 2005;20(9):1647–58.

    Article  CAS  PubMed  Google Scholar 

  55. Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(7):2380–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. Schaffler MB, Burr DB. Stiffness of compact bone: effects of porosity and density. J Biomech. 1988;21(1):13–6.

    Article  CAS  PubMed  Google Scholar 

  57. Patsch JM, Burghardt AJ, Yap SP, et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res. 2013;28(2):313–24.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Samelson E, Bouxsein M, Brochin E, et al. Deficits in cortical bone density and microstructure in type 2 diabetes: Framingham HR-pQCT Study. J Bone Miner Res, 2014. http://www.asbmr.org/education/AbstractDetail?aid=717f3c4f-ac78-4141-be67-445acf5d4c9e (accessed December 12, 2014).

  59. Melton 3rd LJ, Riggs BL, Leibson CL, et al. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metabol. 2008;93(12):4804–9.

    Article  CAS  Google Scholar 

  60. Petit MA, Paudel ML, Taylor BC, et al. Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study. J Bone Miner Res. 2010;25(2):285–91.00.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Funding Source

Columbia University Irving Institute for Clinical and Translational Research CTSA/CTO pilot award.

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

MR Rubin declares no conflicts of interest.

Human and Animal Rights and Informed Consent

All studies by MR Rubin involving animal and/or human subjects were performed after approval by the appropriate institutional review boards. When required, written informed consent was obtained from all participants.

Author information

Authors and Affiliations

  1. Department of Medicine, Metabolic Bone Diseases Unit, College of Physicians and Surgeons, Columbia University, 630 W. 168th St, New York, NY, 10032, USA

    Mishaela R. Rubin

Authors
  1. Mishaela R. Rubin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mishaela R. Rubin.

Additional information

This article is part of the Topical Collection on Bone and Diabetes

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rubin, M.R. Bone Cells and Bone Turnover in Diabetes Mellitus. Curr Osteoporos Rep 13, 186–191 (2015). https://doi.org/10.1007/s11914-015-0265-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-015-0265-0

Keywords

Search

Navigation